Tukysa, a tyrosine kinase inhibitor by Pfizer, delays disease progression in HER2-positive metastatic breast cancer. In a late-stage trial with 654 patients, it improved progression-free survival by 8 ...

Promising data show a median overall survival of 18.6 months, with 40% of patients alive at 2 years.Results suggest that nuclear GSK-3β ...

Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has granted approval to ...

The first-line standard of care for HR-positive/HER2-negative breast cancer is cyclin-dependent kinase (CDK)4/6 inhibitors ...

Preliminary clinical evidence of Lisaftoclax overcoming venetoclax resistance in myeloid malignancies with a 31.8% overall ...

Recent advances in the treatment of non-small cell lung cancer (NSCLC) have led to improved patient outcomes, particularly ...

Financing includes participation from leading institutional investors including Janus Henderson Investors, Brahma Capital, Biotrack Capital, Cormorant Asset Management, OrbiMed, Plaisance Capital ...

Insilico Medicine has developed a new class of small molecule inhibitors targeting diacylglycerol kinase alpha (DGKα) designed to restore T cell function and overcome resistance to immune checkpoint ...

NOTE. P < .00357 represents statistical significance after the Bonferroni correction. Abbreviations: MAPK, mitogen-activated protein kinase; NA, unable to be calculated; NR, not reached; OS, overall ...

The global phosphoinositide 3-kinase inhibitor market is poised to witness significant growth, projected to expand at a robust CAGR of 5.61% during the forecast period from 2019 to 2026.